Study Reveals Cardiolipin's Role in Ageing Muscle Protection
Research indicates that declining cardiolipin levels in muscles may trigger protective adaptations against age-related decline.
Declining cardiolipin levels in muscles may lead to protective adaptations.
Restoring cardiolipin in mice reversed muscle loss and prevented early death.
Potential treatments targeting cardiolipin and ERRγ are being explored.
A recent study from the University of Copenhagen has uncovered a significant mechanism in ageing muscles that may help protect cells from damage. The research indicates that as muscles age, they experience a decline in cardiolipin levels, a crucial molecule found in mitochondrial membranes, which may trigger a shift towards slow-twitch muscle fibers. This adaptation, while leading to a loss of strength, appears to serve as a protective measure against cellular damage.
Historically, muscle strength naturally diminishes with age, and this decline is often attributed to the inefficiency of mitochondria, the energy-producing structures within cells. Surprisingly, the study found that ageing muscles develop a higher proportion of slow-twitch fibers, which rely heavily on mitochondria. This raises questions about why muscles would depend on a less effective energy system. The researchers focused on cardiolipin, which is essential for maintaining mitochondrial function, and discovered that its levels decrease with age, leading to structural abnormalities in mitochondria.
In their experiments, the team observed that reducing cardiolipin levels in young mice replicated the muscle fiber changes seen in older animals. Remarkably, when cardiolipin levels were restored to two-thirds of normal, signs of muscle wasting were reversed, and premature deaths were prevented. The study highlights the role of reactive oxygen species (ROS) produced by damaged mitochondria, which seem to signal the transition from fast-twitch to slow-twitch fibers, indicating a protective response rather than mere muscle failure.
The implications of this research extend beyond basic science, suggesting potential therapeutic avenues for age-related muscle decline. Current FDA-approved treatments targeting cardiolipin, such as elamipretide for Barth syndrome, indicate that influencing cardiolipin levels is feasible. Additionally, ERRγ, a protein that helps muscles adapt to mitochondrial stress, may serve as another target for future therapies.
Looking ahead, researchers are optimistic about the potential to enhance cardiolipin levels in ageing muscles or to manipulate ERRγ to promote healthier muscle adaptations. The findings underscore the importance of understanding the protective mechanisms in ageing muscles, paving the way for innovative treatments aimed at mitigating muscle loss in older adults.
